Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

Pfizer raised its full-year profit forecast on Tuesday after topping Wall Street expectations for second-quarter results as ...

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, ...

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q2 CY2025, with sales up 10.3% year ...